Shots:

• The companies collaborated to assess Turning Point’s elzovantinib (TPX-0022) in combination with EQRx’s aumolertinib in patients with EGFR mutant MET-amplified advanced NSCLC
• Turning Point will sponsor and conduct a P-Ib/II clinical trial to evaluate the safety- tolerability and preliminary efficacy of the combination regimen and will assume all costs associated with the trial whereas EQRx will provide aumolertinib at no cost
• Turning Point is planning to initiate the clinical trial in 2022- pending the filing of an IND application by the US FDA. Preclinical data suggested the combination of MET and EGFR inhibition has the potential to increase anti-tumor activity based on complementary mechanisms

  | Ref: Globe Newswire | Image: Turning Point